Cargando…

Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden

Detalles Bibliográficos
Autor principal:	Egger, Michael E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477633/ https://www.ncbi.nlm.nih.gov/pubmed/37675308 http://dx.doi.org/10.21037/atm-23-597

Ejemplares similares

Might positron emission tomography actually treat micrometastatic cancer?
por: Goldstein, Mark R., et al.
Publicado: (2009)

Characterisation of micrometastatic tumor cells
por: Pantel, K
Publicado: (2000)

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016)

Putative growth characteristics of micrometastatic breast cancer
por: Chambers, Ann F, et al.
Publicado: (2008)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage
por: Heinz, Maria C., et al.
Publicado: (2022)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Commentary: A new PORT in the stage IIIA N2 non–small cell lung cancer storm
por: Ashbrook, Matthew J., et al.
Publicado: (2021)

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
por: Bonin, Serena
Publicado: (2015)

Diabetes‐related cognitive dysfunction: Hyperglycemia in the early stage might be a key?
por: Umegaki, Hiroyuki
Publicado: (2018)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance
por: Fehm, Tanja, et al.
Publicado: (2008)

Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma.
por: Gilbert, J., et al.
Publicado: (1997)

Another debriefing course! Who benefits?
por: Krogh, Kristian, et al.
Publicado: (2018)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Metabolic signature might be an option to identify patients with early CP
por: Erőss, Bálint, et al.
Publicado: (2021)

Knowing who would respond to a recruitment maneuver before actually doing it – this might be a way to go
por: Kuhlen, Ralf
Publicado: (2008)

Staging of cutaneous melanoma
por: Mohr, P., et al.
Publicado: (2009)

Prognostic and Predictive Value of the American Joint Committee on Cancer Pathological Prognostic Staging System in Nodal Micrometastatic Breast Cancer
por: Shi, Jian, et al.
Publicado: (2020)

High-resolution array comparative genomic hybridization of single micrometastatic tumor cells
por: Fuhrmann, Christine, et al.
Publicado: (2008)

Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer.
por: Deguchi, T., et al.
Publicado: (1997)

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination
por: Haffner, Michael C., et al.
Publicado: (2017)

The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives
por: Gkolfinopoulos, Stavros, et al.
Publicado: (2020)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Descriptive epidemiology of cutaneous melanoma – A treasure for generating hypotheses
por: Stang, Andreas, et al.
Publicado: (2021)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Who benefits from putting family life into ice?
por: Hovatta, Outi
Publicado: (2016)

Commentary: When does the burden of treatment outweigh the biological benefit?
por: Blumenthaler, Alisa N., et al.
Publicado: (2020)

Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
por: Bailey-Downs, Lora C., et al.
Publicado: (2014)

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

The injured brain might need more fat!
por: Hyacinth, Hyacinth I.
Publicado: (2018)

COVID-19: When more might be less
por: Mugnai, Giacomo, et al.
Publicado: (2021)

Accelerated partial breast irradiation: technically feasible but who will benefit?
por: Ross, Gillian
Publicado: (2005)

Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics?
por: Harvima, Ilkka T., et al.
Publicado: (2022)

Re: Making Health and Care Systems Fit for and Ageing Population. Why We Wrote It, Who We Wrote It For, and How Relevant It Might Be to Canada
por: Oliver, David
Publicado: (2014)

Prognosis and local treatment strategies of breast cancer patients with different numbers of micrometastatic lymph nodes
por: Luo, Shiping, et al.
Publicado: (2023)

Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model
por: Pillai, Sreeraj G., et al.
Publicado: (2018)

Commentary: The correct answer is not true or false, but the ratio might be
por: Atkins, Marvin D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oq8v7no91jpbhvmvjsb3f9qc0b